Medicamen Biotech Ltd's Q4FY25 Quarterly Results

Result Summary

• Medicamen Biotech Ltd reported a 5.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 22.8%.
• Its expenses for the quarter were up by 9.2% QoQ and 30.5% YoY.
• The net profit decreased 30.1% QoQ and decreased 45.9% YoY.
• The earnings per share (EPS) of Medicamen Biotech Ltd stood at 1.6 during Q4FY25.

Financial Statments for Q4FY25

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Medicamen Biotech Ltd is a pharmaceutical company that operates within the healthcare industry. The company primarily focuses on the development, manufacturing, and marketing of pharmaceutical products. These products include a range of formulations that cater to both domestic and international markets. While specific details about recent major developments are not provided, it is common for companies in this sector to engage in activities such as expanding their product portfolio, entering new markets, or enhancing manufacturing capabilities. If there are any significant recent developments, such information is not available in the provided dataset.

Revenue

For Q4FY25, Medicamen Biotech Ltd reported total income of ₹47.89 crores, which marks an increase from ₹45.28 crores in Q3FY25 and ₹39.01 crores in Q4FY24. The quarter-over-quarter (QoQ) growth in total income was 5.8%, while the year-over-year (YoY) growth was 22.8%. This data indicates a positive growth trajectory in terms of revenue generation for the company over both the short term (quarterly) and long term (yearly) periods, reflecting an increase in business operations or sales activities when compared to previous periods.

Profitability

The company's profit before tax for Q4FY25 was ₹2.66 crores, which decreased from ₹3.88 crores in Q3FY25 and ₹4.36 crores in Q4FY24. This reflects a QoQ decrease of 31.4% and a YoY decrease of 39.0%. Tax expenses for Q4FY25 were ₹0.62 crores, down from ₹0.96 crores in Q3FY25, yet slightly higher than the ₹0.59 crores recorded in Q4FY24. The net profit or profit after tax for Q4FY25 was ₹2.04 crores, showing a decline from ₹2.92 crores in the previous quarter and ₹3.77 crores in the same quarter of the previous year. These numbers represent a QoQ decrease of 30.1% and a YoY decline of 45.9% in net profitability. Earnings per share (EPS) also decreased to ₹1.60 from ₹2.30 in Q3FY25 and ₹3.00 in Q4FY24, corresponding to a QoQ decrease of 30.4% and a YoY decrease of 46.7%.

Operating Metrics

Total expenses for Q4FY25 were recorded at ₹45.23 crores, which is an increase from ₹41.41 crores in Q3FY25 and ₹34.66 crores in Q4FY24. This indicates a 9.2% increase QoQ and a 30.5% increase YoY in expenses. The increase in total expenses over both quarterly and yearly comparisons reflects higher operational costs or investments made by the company. The decline in profitability despite an increase in revenue could be attributed to these rising expenses. Such changes in operating metrics provide a snapshot of the cost dynamics and efficiency-related aspects of the company's operations over the specified periods.